哌嗪-2,6-二酮盐酸盐 | 35975-30-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 哌嗪-2,6-二酮盐酸盐
• 英文名称: piperazine-2,6-dione hydrochloride
• 英文别名: piperazinedione-2,6 hydrochloride；piperazine-2,6-dione; hydrochloride；Piperazin-2,6-dion; Hydrochlorid；2,6-piperazinedione hydrochloride；Piperazin-4-ium-2,6-dione;chloride；piperazin-4-ium-2,6-dione;chloride
• CAS: 35975-30-5
• 化学式: C₄H₆N₂O₂*ClH
• 分子量: 150.565
• InChiKey: PRECVFCPUGFXKR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.35
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.2
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  哌嗪-2,6-二酮盐酸盐 、 3-硝基苯磺酰氯 在 potassium hydrogencarbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 13.0h， 以64.4%的产率得到Cambridge id 5650337
  参考文献：
  名称：

  Synthesis and antiinflammatory activity of 4-acyl and 4-sulfonyl derivatives of piperazine-2,6-dione

  摘要：

  DOI：

  10.1007/bf02509951
• 作为产物：
  描述：

  4-benzyl-piperazine-2,6-dione 在 盐酸 、 氢气 作用下， 以 甲醇 、 水 为溶剂， 以28%的产率得到哌嗪-2,6-二酮盐酸盐
  参考文献：
  名称：

  [EN] NOVEL ACYLPIPERAZINONES AND THEIR USE AS PHARMACEUTICALS
  [FR] NOUVELLES ACYLPIPÉRAZINONES ET LEUR UTILISATION EN TANT QUE PHARMACEUTIQUES

  摘要：

  这项发明涉及新型酰基哌嗪酮化合物，涉及该化合物及其中间体的制备，涉及将该化合物用作抗菌药物以及含有该化合物的药物组合物的用途。

  公开号：

  WO2011048153A1

文献信息

• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• TRICYCLIC COMPOUND
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1939205A1

  公开（公告）日：2008-07-02

  The present invention relates to tricyclic compounds each represented by the following formula (I): (wherein, R1, R2, R2', R3, R4, X, Y and Z have the same meanings as defined in the specification); and a drug containing the compound. Since the compounds according to the present invention exhibit an excellent squalene synthetase inhibitory effect and cholesterol synthesis inhibitory effect so that they are useful as a drug such as preventive and/or remedy for diseases in mammals including humans such as hyperlipemia, e.g., hypercholesterolemia, hypertriglyceridemia, and low HDL cholesterolemia and/or arteriosclerosis.

  本发明涉及一种三环化合物，每种化合物由以下式（I）表示：（其中，R1、R2、R2'、R3、R4、X、Y和Z的含义与规范中定义的含义相同）；以及含有该化合物的药物。由于根据本发明的化合物表现出优异的角鲨烯合酶抑制作用和胆固醇合成抑制作用，因此它们可用作哺乳动物（包括人类）的疾病预防和/或治疗药物，例如高脂血症，如高胆固醇血症、高甘油三酯血症、低高密度脂蛋白胆固醇血症和/或动脉粥样硬化。
• [EN] HETEROATOM CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS<br/>[FR] HÉTÉROATOME CONTENANT DES INHIBITEURS DE LA DÉSOXYURIDINE TRIPHOSPHATASE
  申请人：UNIV SOUTHERN CALIFORNIA

  公开号：WO2015103489A1

  公开（公告）日：2015-07-09

  Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions in a method of treating cancer. The dUTPase inhibitors disclosed contain a uracil isostere in the molecule represented by a 2,6-diketopiperazine moiety. Thioanalogs of the uracil isostere where a thione replaces each of the ketone are also disclosed.

  本文提供了dUTPase抑制剂，包括这些化合物的组合物和使用这些化合物和组合物治疗癌症的方法。所述的dUTPase抑制剂分子中含有一个由2,6-二酮哌嗪基团表示的尿嘧啶同构体。还披露了尿嘧啶同构体的硫代衍生物，其中硫醇代替了酮基。
• Pyrazole Derivatives
  申请人：Kanaya Naoaki

  公开号：US20080064682A1

  公开（公告）日：2008-03-13

  A compound represented by formula (I): (wherein Ar 1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar 2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, a sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  化合物的化学式为(I)：其中Ar1代表一个苯基，它可能有1到3个取代基，或者是一个非取代的5-或6-成员的芳香杂环基；Ar2代表(i)一个非取代的苯基，(ii)一个已经被1到3个来自羰基基团、氨基基团、羟基基团、低级烷氧基团和卤原子的较低烷基取代的苯基，或者(iii)一个已经被1到3个来自较低烷基、较低炔基、较低烷酰基、羰基基团、氰基基团、氨基基团、羟基基团、低级烷氧基团和卤原子的取代的5-或6-成员的含氮芳香杂环基；X代表一个化学式(II)所代表的基团：(其中环结构代表一个4-到7-成员的杂环基，它可能有除了在化学式(II)中显示的氮原子之外的一个来自氮、氧、硫的杂原子，它可能被1到4个来自较低烷基、羰基基团、氨基基团、羟基基团、低级烷氧基团、氧基基团、较低烷酰基、较低烷基磺酰基和卤原子的取代基所取代)，它的盐、该化合物或其盐的溶剂化物，以及药物。
• NOVEL ACYLPIPERAZINONES AND THEIR USE AS PHARMACEUTICALS
  申请人：FAB PHARMA S.A.S.

  公开号：US20130137689A1

  公开（公告）日：2013-05-30

  The invention relates to novel acylpiperazinone compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.

  本发明涉及新型酰基哌嗪酮化合物，以及制备该化合物和其中间体的方法，利用该化合物作为抗菌药物和含有该化合物的制药组合物。